Fruquintinib after immunotherapy for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called fruquintinib for people with advanced liver cancer who have already tried immunotherapy. It may help shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of liver cancer called hepatocellular carcinoma (HCC) that cannot be removed by surgery.
- You have already received immunotherapy (a treatment that helps your immune system fight cancer).
- You have at least one tumor that can be seen on a scan.
- You are able to take care of yourself (ECOG score 0 or 1).
- Your liver function is stable (Child-Pugh score 7 or less) and blood counts are within certain limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called fruquintinib, given alone or with a chemotherapy infusion directly into your liver, for people whose colorectal cancer has spread to the liver and has stopped responding to standard treatments. It aims to find a new option for patients with limited cancer outside the liver.
This trial tests a modified version of the drug fruquintinib for people with colorectal cancer that has spread to the liver. It is for those who have had successful liver-directed treatment (surgery, ablation, or radiation) and have no signs of cancer left, then finished chemotherapy without the cancer growing back.
This trial tests a new combination of three drugs (fruquintinib, camrelizumab, and capecitabine) for people with colorectal cancer that has spread or cannot be removed and has stopped responding to a standard first chemotherapy. It is for those whose cancer progressed after a specific first treatment called FOLFOXIRI.
This trial tests a combination of an oral targeted therapy (fruquintinib), an immunotherapy (PD-1 inhibitor), and chemotherapy (FOLFOX) as the first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if this triplet therapy helps control the cancer better than standard treatments.
This study tracks how well fruquintinib works for people with advanced colorectal cancer that has spread. It aims to find factors that predict better outcomes, using blood and tumor samples.
This trial studies fruquintinib combined with serplulimab (an immune therapy) for advanced colorectal cancer that has spread and is no longer responding to standard treatments. It may help by slowing the cancer’s growth and improving outcomes after the usual options have been tried.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.